- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02479490
PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI (PREV)
Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors
This is a multicenter prospective study that includes all patients with metastatic Renal Cell Cancer (RCC) pre- treated with VEGFR TKI in eight Italian cancer centers.
Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.
A treatment cycle consists of 28 days.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Title Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitor (PREV study).
Short Title/ Acronym PREV Protocol Code IRST189.04 Phase Phase 2 Study Design This is a multicenter prospective study that includes all patients with metastatic RCC pre- treated with VEGFR TKI in eight Italian cancer centers.
Study Duration 2 years of recruitment and 1 year of follow-up Study Center(s) multi-center: 8 centers involved
Objectives Primary objective:
To evaluate the safety and tolerability of prednisone 5 mg bid and everolimus 10 mg/day in RCC.
Secondary objectives:
To evaluate the activity and the clinical outcome of these patients.
Exploratory objectives:
To evaluate the influence of prednisone on trough concentration of everolimus and correlation with the incidence of side effects, in particular stomatitis and non-infectious pneumonitis.
Infiammation markers such as pentraxin 3 (PTX3), IL-6, TGF-β and neutrophil-lymphocyte ratio will be correlated with clinical outcome (ORR, PFS, OS).
Number of Subjects 42 subjects Diagnosis and Main Inclusion Criteria Patients with mRCC who failed at least one VEGFR TKI.
Main Inclusion Criteria:
- Patients with renal cell carcinoma who failed at least one VEGFR TKI
- Patients with adequate bone marrow function
- Patients with adequate liver function
- Patients with adequate renal function Diagnosis and Main Inclusion Criteria (continued) Main exclusion criteria:
- CNS disease OR patients with presence or history of central nervous system (CNS) lymphoma
- Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone ≤ 20 mg for adrenal insufficiency). However, patients receiving corticosteroids must be on a stable dose for ≥ 4 weeks prior to the first dose of everolimus. Topical or inhaled corticosteroids are permitted.
- Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
- Patients with uncontrolled hyperlipidemia (≥ Grade 3 hyperlipidemia despite optimal supportive medical therapy)
- Patients with an active, bleeding diathesis
- Previous organ transplantation
- Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Study Product, Dose, Route, Regimen and duration of administration Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.
A treatment cycle consists of 28 days. Reference therapy Not applicable Statistical Methodology This is a multicenter prospective study that includes all patients with metastatic RCC pre- treated with VEGFR TKI in eight Italian cancer centers.
The study will be analyzed on an intent-to-treat basis. Secondary parameters will be analyzed exploratively for the intent-to-treat population.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Rimini, Italy, 47923
- Oncologia Medica, PO Rimini-Cattolica, AUSL della Romagna
-
-
FC
-
Meldola, FC, Italy, 47014
- U.O Oncologia Medica, IRST IRCCS
-
-
RA
-
Faenza, RA, Italy, 48121
- Oncologia Medica, PO Faenza, AUSL della Romagna
-
Ravenna, RA, Italy, 48121
- Oncologia Medica, PO RAVENNA, AUSL della Romagna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Patients with histopathologically confirmed diagnosis of renal cell carcinoma
- Patients with renal cell carcinoma who failed at least one VEGFR TKI
- Patients with adequate bone marrow function defined as ANC ≥ 1.5 x 109/L, Platelets ≥ 80 x 109/L, Hb >9 g/dL
- Patients with adequate liver function defined as serum bilirubin ≤ 1.5 x ULN, ALT and AST ≤ 2.5x ULN. Patients with known liver metastases who have an AST and ALT ≤ 5x ULN
- Patients with adequate renal function defined as serum creatinine ≤ 1.5 x ULN
- Patients who give a written informed consent obtained according to local guidelines
Exclusion Criteria:
- CNS disease OR patients with presence or history of central nervous system (CNS) lymphoma
- Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone ≤ 20 mg for adrenal insufficiency). However, patients receiving corticosteroids must be on a stable dose for ≥ 4 weeks prior to the first dose of everolimus. Topical or inhaled corticosteroids are permitted.
- Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
- Patients with uncontrolled hyperlipidemia (≥ Grade 3 hyperlipidemia despite optimal supportive medical therapy)
- Patients with an active, bleeding diathesis
- Previous organ transplantation
Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
- unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
- severely impaired lung function (spirometry and DLCO that is 50% of the normal predicted value and/or Oxygen saturation that is 88% or less at rest, in room air)
- uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
- any active (acute or chronic) or uncontrolled infections/disorders
- non malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with this study therapy
- liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
- Note: a detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV DNA and HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.
- A known history of HIV seropositivity
- Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not willing to use effective birth control methods. If barrier contraceptives are used, they must be continued throughout the treatment by both sexes.
- Patients unwilling to or unable to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prednisone + Everolimus
|
Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason. A treatment cycle consists of 28 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safety and tolerability evaluation (incidence of grade ≥ 2 stomatitis and non-infectious pneumonitis)
Time Frame: up to 36 months
|
to evaluate the incidence of grade ≥ 2 stomatitis and non-infectious pneumonitis in RCC patients treated with prednisone 5 mg bid and everolimus 10 mg/day.
|
up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: up to 36 months
|
the sum of partial responses plus complete responses
|
up to 36 months
|
Progression free survival (PFS)
Time Frame: up to 36 months
|
time from the date of starting of the treatment to the date of the first observation of documented disease progression or death due to any cause.
Patients without tumor progression at the time of analysis will be censored at their last date of tumor evaluation.
|
up to 36 months
|
Overall survival (OS)
Time Frame: up to 36 months
|
time from the date of starting of the treatment to the date of the death due to any cause.
Patients living at the time of analysis will be censored at their last date of tumor evaluation.
|
up to 36 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisone
- Everolimus
Other Study ID Numbers
- IRST189.04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Renal Cancer
-
Novartis PharmaceuticalsTerminatedMetastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal FunctionBelgium
-
NewLink Genetics CorporationCompletedMetastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal CancerUnited States
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedMetastatic Renal Cell Carcinoma | Metastatic Kidney CancerFrance
-
Institut Claudius RegaudCompletedMetastatic Urothelial Cancer | Advanced Urothelial CancerFrance
-
Duke UniversityCompletedMetastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
National Cancer Institute (NCI)RecruitingClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Soft Tissues | Metastatic Malignant Neoplasm in the Viscera and other conditionsUnited States, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Centre Georges Francois LeclercRecruitingMetastatic Renal Cell Carcinoma | Metastatic Non Small Cell Lung Cancer | Metastatic Head and Neck Cancer | Metastatic Bladder CancerFrance
-
Tampere University HospitalUniversity of Turku; University of Helsinki; Tampere University; Aalto UniversityRecruitingKidney Cancer | Breast Cancer | Metastatic Renal Cell Carcinoma | Ovarian Cancer | Prostate Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Ovarian Cancer | Metastatic Renal Cancer | Metastatic Kidney Cancer | Metastatic Ovary CancerFinland
-
Western Regional Medical CenterTerminatedKidney Cancer Metastatic | Renal Cell Cancer MetastaticUnited States
Clinical Trials on Prednisone + Everolimus
-
Fundação Pró RimUnknown
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
Helio Tedesco Silva JuniorSanofi; NovartisCompletedKidney Transplantation | CytomegalovirusBrazil
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
The Netherlands Cancer InstituteActive, not recruitingNeuroendocrine CarcinomasNetherlands
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
University of LuebeckTerminatedCoronary Artery DiseaseGermany
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of